Breaking News

PharmaJet Announces Government Award Expansion to Clinically Assess a DNA Vaccine

Follow-on award under a multi-year agreement with the U.S. Defense Threat Reduction Agency.

PharmaJet, a company engineering precision delivery systems (PDS) that overcome the challenges of vaccine delivery, received a 3-year extension of its multi-year agreement with the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency (DTRA). The expansion award, worth over $4 million, will be used to further advance the clinical assessment of its Venezuelan Equine Encephalitis Virus (VEEV) DNA candidate vaccine in combination with either Tropis Intradermal (ID) or S...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters